Severe/Extreme Hypertriglyceridemia and LDL Apheretic Treatment: Review of the Literature, Original Findings | Zendy

Olga Diakoumakou | Zendy; Georgios Hatzigeorgiou | Zendy; Nikos Gontoras | Zendy; Maria Boutsikou | Zendy; Vana Kolovou | Zendy; Sophie Mavrogeni | Zendy; Vassiliki Giannakopoulou | Zendy; Genovefa Kolovou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Severe/Extreme Hypertriglyceridemia and LDL Apheretic Treatment: Review of the Literature, Original Findings

Author(s) -

Olga Diakoumakou,

Georgios Hatzigeorgiou,

Nikos Gontoras,

Maria Boutsikou,

Vana Kolovou,

Sophie Mavrogeni,

Vassiliki Giannakopoulou,

Genovefa Kolovou

Publication year - 2014

Publication title -

cholesterol

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.876

H-Index - 20

eISSN - 2090-1291

pISSN - 2090-1283

DOI - 10.1155/2014/109263

Subject(s) - medicine , hypertriglyceridemia , metabolic syndrome , disease , diabetes mellitus , coronary artery disease , atherosclerotic cardiovascular disease , bioinformatics , intensive care medicine , pediatrics , triglyceride , endocrinology , cholesterol , biology

Hypertriglyceridemia (HTG) is a feature of numerous metabolic disorders including dyslipidemias, metabolic syndrome, and diabetes mellitus type 2 and can increase the risk of premature coronary artery disease. HTG may also be due to genetic factors (called primary HTG) and particularly the severe/extreme HTG (SEHTG), which is a usually rare genetic disorder. Even rarer are secondary cases of SEHTG caused by autoimmune disease. This review considers the causes of SEHTG, and their management including treatment with low density lipoprotein apheresis and analyzes the original findings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research